Increases in drug prices are of concern to worldwide health systems

By HEOR Staff Writer

March 17, 2023

In surveys of ISPOR members, drug pricing was revealed to be a major concern, and one of the top 10 health economics and outcomes research issues influencing the availability of innovative treatments and healthcare decisions.

Despite the fascinating ways that different research studies proposed to understand the puzzle of drug pricing, it is evident that drug prices must factor in the research uncertainties and other costs in addition to the cost of clinical trials and production and should be set to yield an acceptable return on investment.

There has been a lot of discussion about the fairness of drug pricing. The concept is multifaceted, and when discussing it, drug characteristics and market forces must be included. This conversation is further complicated by the lack of transparency in drug pricing and the rise in drug prices.

It is likely that the debate will persist.

Reference url

Recent Posts

European pharmacists preparation
European Pharmacists Preparation for Health Crisis Response

By João L. Carapinha

May 29, 2026

European pharmacists preparation ensures that community networks remain operational during health crises, enabling continuous patient care amid pandemics and infrastructure failures. The recently published PGEU position paper outlines seven priorities that integrate pharmacies into governance str...
Radioligand Therapy Prostate Cancer
Advancements in Radioligand Therapy Prostate Cancer Treatment
Radioligand Therapy Prostate Cancer has emerged as a breakthrough approach in prostate cancer treatment by linking a cancer-targeting molecule to a radioactive payload that delivers radiation directly to tumor cells. This method minimizes damage to nearby healthy tissue while demonstrating clinic...
Conversational Agent Interventions
Therapeutic Impact of Conversational Agent Interventions on Mental Health
Conversational Agent Interventions demonstrate measurable benefits for mental health, according to a meta-analysis of 48 randomized controlled trials involving 28,071 participants that found both AI-based and rule-based agents produced small-to-moderate reductions in depression (SMD −0.27), anxie...